Get the app
US › Healthcare

Edesa Biotech Inc (EDSA)

US · Healthcare · Biotechnology

$2.57-3.75%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-5.4M
EPS
$-0.60
EPS estimate
$-0.44

EPS came in at -0.60 against a street estimate of -0.44 — a miss of 36.4%.

Key statistics

Market cap
$38.4M
Forward P/E
0.2
P/B
96.90
Book value
$0.04
EPS (TTM)
$-1.72
52-week high
$20.32
52-week low
$0.72
50-day MA
$4.52
200-day MA
$5.57
Beta
1.22

Analyst view

Analysts rate Edesa Biotech Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $16.33.

Shareholding

Insiders
13.55%
Institutions
37.44%

Largest institutional holders

FundStake
Velan Capital Investment Management LP6.12%
Rubric Capital Management LP4.96%
Perceptive Advisors LLC4.17%
Millennium Management LLC4.16%
Stonepine Capital Management Llc3.38%
Boxer Capital Management, LLC1.52%
Vanguard Capital Management, LLC0.61%
Geode Capital Management, LLC0.60%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Edesa Biotech Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.